Lawsuits Pile Up Alleging Remdesivir Killed COVID Patients


 By Dr. Joseph Mercola

The U.S. Food and Drug Administration (FDA) authorized the experimental antiviral drug remdesivir, brand name Veklury, for emergency use against COVID-19 in May 2020.

By October 2020, it had received full approval. It remains a primary treatment for COVID-19 in hospitals, despite research showing it lacks effectiveness and can cause high rates of organ failure.

On Twitter, John Beaudoin is calling for a criminal investigation into the drug, citing data that it may have killed 100,000 people in the U.S.

"They know," he says, "or they willfully refuse to know. Either way, it's homicide."

Using drugs that cause organ failure, like remdesivir, isn't in the best interest of public health. The fact that U.S. health authorities have focused on this and similarly harmful drugs to the exclusion of all others, including older drugs with high rates of effectiveness and superior safety profiles, sends a very disturbing message.

Did remdesivir kill thousands in Massachusetts?

Beaudoin has filed a lawsuit in U.S. District Court and believes a spike in deaths from acute renal failure (ARF) in Massachusetts is due to remdesivir, which is produced by Gilead Sciences.

Using a Freedom of Information Act (FOIA) request, Beaudoin received all the death certificates in Massachusetts from 2015 to 2022.

He then graphed the FOIA data, finding 1,840 excess deaths from acute renal failure from Jan. 1, 2021 to Nov. 30, 2022. Beaudoin also revealed an increase in deaths from acute rental failure in every age group over 15 years old, from 2015 to 2022.